搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
centerforbiosimilars
5 小时
IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...
centerforbiosimilars
23 小时
BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
centerforbiosimilars
1 天
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
centerforbiosimilars
7 天
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...
centerforbiosimilars
5 天
The Top 5 Biosimilar Articles for the Week of September 16
Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new ...
centerforbiosimilars
9 天
STADA Credits Biosimilar Expansion for Profitable First Half of 2024
German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 ...
centerforbiosimilars
8 天
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of ...
centerforbiosimilars
15 天
Patients With nAMD Successfully Switch From Aflibercept to Ranibizumab
A study found patients with neovascular age-related macular degeneration (nAMD) successfully switched from aflibercept to the ...
centerforbiosimilars
8 天
FDA Approves Pavblu for Retinal Conditions
Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American ...
centerforbiosimilars
14 天
The Future of Biosimilar Gene Therapies: Key Issues and Potential
While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, ...
centerforbiosimilars
16 天
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes ...
centerforbiosimilars
3 天
The Role of Risk-Sharing Models in Biosimilar Adoption
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈